Among its subtypes, triple-negative breast cancer (TNBC) remains a major clinical challenge as it lacks estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) [2,3]. This evidence concerns the gene PGR and triple-negative breast carcinoma.